Your browser doesn't support javascript.
loading
Protease-activated receptors (PARs)--biology and role in cancer invasion and metastasis.
Wojtukiewicz, Marek Z; Hempel, Dominika; Sierko, Ewa; Tucker, Stephanie C; Honn, Kenneth V.
Afiliação
  • Wojtukiewicz MZ; Department of Oncology, Medical University of Bialystok, 12 Ogrodowa St., 15-025, Bialystok, Poland. mzwojtukiewicz@gmail.com.
  • Hempel D; Department of Clinical Oncology, Comprehensive Cancer Center , Bialystok, Poland. mzwojtukiewicz@gmail.com.
  • Sierko E; Department of Oncology, Medical University of Bialystok, 12 Ogrodowa St., 15-025, Bialystok, Poland.
  • Tucker SC; Department of Clinical Oncology, Comprehensive Cancer Center , Bialystok, Poland.
  • Honn KV; Department of Radiotherapy, Comprehensive Cancer Center, Bialystok, Poland.
Cancer Metastasis Rev ; 34(4): 775-96, 2015 Dec.
Article em En | MEDLINE | ID: mdl-26573921
ABSTRACT
Although many studies have demonstrated that components of the hemostatic system may be involved in signaling leading to cancer progression, the potential mechanisms by which they contribute to cancer dissemination are not yet precisely understood. Among known coagulant factors, tissue factor (TF) and thrombin play a pivotal role in cancer invasion. They may be generated in the tumor microenvironment independently of blood coagulation and can induce cell signaling through activation of protease-activated receptors (PARs). PARs are transmembrane G-protein-coupled receptors (GPCRs) that are activated by a unique proteolytic mechanism. They play important roles in vascular physiology, neural tube closure, hemostasis, and inflammation. All of these agents (TF, thrombin, PARs-mainly PAR-1 and PAR-2) are thought to promote cancer invasion and metastasis at least in part by facilitating tumor cell migration, angiogenesis, and interactions with host vascular cells, including platelets, fibroblasts, and endothelial cells lining blood vessels. Here, we discuss the role of PARs and their activators in cancer progression, focusing on TF- and thrombin-mediated actions. Therapeutic options tailored specifically to inhibit PAR-induced signaling in cancer patients are presented as well.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor PAR-1 / Receptor PAR-2 / Invasividade Neoplásica / Metástase Neoplásica / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptor PAR-1 / Receptor PAR-2 / Invasividade Neoplásica / Metástase Neoplásica / Neoplasias Limite: Humans Idioma: En Ano de publicação: 2015 Tipo de documento: Article